NO940564L - - Google Patents

Info

Publication number: NO940564L
Authority: NO; Norway
Prior art keywords: dried; sterile freeze; cetrorelix acetate; treatment; gonads
Prior art date: 1993-02-19

Application number

NO940564A

Other languages

English (en)

Norwegian (no)

Other versions

NO316601B1 (no

NO940564D0 (no

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-19

Filing date

1994-02-18

Publication date

1994-08-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6480924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO940564(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-02-18 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1994-02-18 Publication of NO940564D0 publication Critical patent/NO940564D0/no

1994-08-22 Publication of NO940564L publication Critical patent/NO940564L/no

2004-03-08 Publication of NO316601B1 publication Critical patent/NO316601B1/no

Links

108700008462 cetrorelix Proteins 0.000 abstract 4
229960001865 cetrorelix acetate Drugs 0.000 abstract 4
KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 abstract 4
208000007984 Female Infertility Diseases 0.000 abstract 2
206010021928 Infertility female Diseases 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
238000002512 chemotherapy Methods 0.000 abstract 2
210000004602 germ cell Anatomy 0.000 abstract 2
210000002149 gonad Anatomy 0.000 abstract 2
230000001473 noxious effect Effects 0.000 abstract 2
239000000546 pharmaceutical excipient Substances 0.000 abstract 2
230000005855 radiation Effects 0.000 abstract 2
239000000824 cytostatic agent Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Manufacture Of Tobacco Products (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Compounds Of Unknown Constitution (AREA)

NO940564A 1993-02-19 1994-02-18 Ny fremgangsmåte for fremstilling av et sterilt Cetrorelix-lyofilisat NO316601B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4305225A DE4305225A1 (de)	1993-02-19	1993-02-19	Neues Herstellverfahren für Cetrorelix Lyophilisat

Publications (3)

Publication Number	Publication Date
NO940564D0 NO940564D0 (no)	1994-02-18
NO940564L true NO940564L (zh)	1994-08-22
NO316601B1 NO316601B1 (no)	2004-03-08

Family

ID=6480924

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO940564A NO316601B1 (no)	1993-02-19	1994-02-18	Ny fremgangsmåte for fremstilling av et sterilt Cetrorelix-lyofilisat

Country Status (29)

Country	Link
EP (2)	EP0947200B1 (zh)
JP (1)	JP4033919B2 (zh)
KR (2)	KR100355686B1 (zh)
CN (1)	CN1109557C (zh)
AT (1)	ATE193653T1 (zh)
AU (1)	AU671881C (zh)
BR (1)	BR9400617A (zh)
CA (1)	CA2115943C (zh)
CZ (2)	CZ285768B6 (zh)
DE (2)	DE4305225A1 (zh)
DK (1)	DK0611572T3 (zh)
ES (1)	ES2148247T3 (zh)
FI (1)	FI110059B (zh)
GR (1)	GR3034237T3 (zh)
HR (1)	HRP940117B1 (zh)
HU (1)	HU218281B (zh)
IL (1)	IL108704A (zh)
MX (1)	MX9401312A (zh)
NO (1)	NO316601B1 (zh)
NZ (2)	NZ250906A (zh)
PL (1)	PL177177B1 (zh)
PT (1)	PT611572E (zh)
RU (1)	RU2145234C1 (zh)
SG (1)	SG46632A1 (zh)
SI (1)	SI9400087B (zh)
SK (2)	SK283021B6 (zh)
TW (1)	TW387812B (zh)
UA (1)	UA43829C2 (zh)
ZA (1)	ZA941136B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6828415B2 (en) *	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
AR006598A1 (es) *	1996-04-19	1999-09-08	Merck Sharp & Dohme	"composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
DE19712718C2 (de) *	1997-03-26	1999-09-23	Asta Medica Ag	Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
HU228736B1 (en) *	1998-04-23	2013-05-28	Zentaris Ivf Gmbh	Use of lhrh atnagonists in the production of pharmaceutical compostion for the treatment of fertility disorders
DE10024451A1 (de) *	2000-05-18	2001-11-29	Asta Medica Ag	Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
DE10040700A1 (de) *	2000-08-17	2002-02-28	Asta Medica Ag	Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
DE10157628A1 (de) *	2001-11-26	2003-06-12	Zentaris Ag	Injektionslösung eines LHRH-Antagonisten
US20030186892A1 (en) *	2002-03-28	2003-10-02	Rajneesh Taneja	Enhancement of endogenous gonadotropin production
DK1565160T3 (da)	2002-09-27	2014-04-28	Terna Zentaris Gmbh	Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf
EP1722819B1 (en)	2004-03-12	2007-12-26	Intercell AG	Method for solubilising peptide mixtures
EP1674082A1 (de)	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
TWI539959B (zh) *	2008-02-11	2016-07-01	菲瑞茵國際中心股份有限公司	治療轉移階段攝護腺癌的方法
CN101629758B (zh) *	2008-07-19	2012-09-26	浙江家泰电器制造有限公司	液体加热器皿过热保护控制器组件
CN101630607B (zh) *	2008-07-19	2012-04-25	浙江家泰电器制造有限公司	液体加热器皿过热保护控制器组件
RU2454221C2 (ru) *	2010-07-06	2012-06-27	Общество с ограниченной ответственностью "Завод Медсинтез"	Способ получения лиофилизированного противовирусного средства
EP2648755A1 (en)	2010-12-06	2013-10-16	Astron Research Limited	A stable ready-to-use cetrorelix injection
GB201022147D0 (en) *	2010-12-31	2011-02-16	Immune Targeting Systems Its Ltd	Formulation
CN102423484B (zh) *	2011-11-23	2014-01-15	深圳翰宇药业股份有限公司	一种稳定的西曲瑞克药物组合物及其制备方法
EP3015553A1 (de)	2014-10-30	2016-05-04	Biotecon Diagnostics GmbH	Stabilisierte Reaktionsmischung
RU2667128C2 (ru)	2016-12-29	2018-09-14	Герман Петрович Беккер	Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе
WO2020254952A1 (en)	2019-06-17	2020-12-24	Intas Pharmaceuticals Ltd.	A stable formulation of cetrorelix
CN112717119B (zh) *	2021-01-27	2024-04-30	南京羚诺生物医药技术研究院有限公司	一种西曲瑞克药物组合物及其制备方法
US20240123021A1 (en)	2021-06-25	2024-04-18	Extrovis Ag	Pharmaceutical compositions
CN114159544A (zh) *	2022-01-24	2022-03-11	福州华为医药技术开发有限公司	注射用醋酸西曲瑞克及其制备方法
CN115969954A (zh) *	2023-01-09	2023-04-18	开封明仁药业有限公司	一种注射用西曲瑞克冻干药物组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3816386A (en) *	1972-06-20	1974-06-11	Abbott Lab	Purification process for gn-rh
DD141996A1 (de) *	1979-02-21	1980-06-04	Ingrid Wolf	Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
CS230614B1 (en) *	1982-08-06	1984-08-13	Martin Cs Flegel	Analogues of realising factor for luteining and folliculstimulated hormon
US4565804A (en) *	1984-09-07	1986-01-21	The Salk Institute For Biological Studies	GnRH Antagonists VI
EP0268066A3 (en) *	1986-10-17	1990-07-11	Syntex (U.S.A.) Inc.	Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
DE3735614A1 (de) *	1986-10-31	1988-07-28	Asta Pharma Ag	Ifosfamid-lyophilisat und verfahren zu dessen herstellung
DK49987A (da) *	1987-01-30	1988-07-31	Nordisk Gentofte	Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
US4801577A (en) *	1987-02-05	1989-01-31	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4800191A (en) *	1987-07-17	1989-01-24	Schally Andrew Victor	LHRH antagonists
NZ226170A (en) *	1987-09-18	1990-07-26	Ethicon Inc	Stable freeze-dried pharmaceutical composition containing epidermal growth factor
FR2635006B1 (fr) *	1988-08-02	1990-10-19	Letourneur Bernard	Medicament destine a regulariser les secretions hormonales et a traiter la sterilite
US5180711A (en) *	1990-06-14	1993-01-19	Applied Research Systems Ars Holding N.V.	Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
CN1036343C (zh) *	1990-11-10	1997-11-05	天津市计划生育研究所	新促黄体生成素释放激素拮抗类似物的制备方法

1993
- 1993-02-19 DE DE4305225A patent/DE4305225A1/de not_active Ceased
1994
- 1994-01-31 TW TW083100769A patent/TW387812B/zh not_active IP Right Cessation
- 1994-02-04 DK DK94101672T patent/DK0611572T3/da active
- 1994-02-04 EP EP99102340.9A patent/EP0947200B1/de not_active Expired - Lifetime
- 1994-02-04 PT PT94101672T patent/PT611572E/pt unknown
- 1994-02-04 ES ES94101672T patent/ES2148247T3/es not_active Expired - Lifetime
- 1994-02-04 AT AT94101672T patent/ATE193653T1/de active
- 1994-02-04 EP EP94101672A patent/EP0611572B1/de not_active Expired - Lifetime
- 1994-02-04 SG SG1996006874A patent/SG46632A1/en unknown
- 1994-02-04 DE DE59409389T patent/DE59409389D1/de not_active Expired - Lifetime
- 1994-02-14 CZ CZ98974A patent/CZ285768B6/cs not_active IP Right Cessation
- 1994-02-14 CZ CZ94312A patent/CZ284314B6/cs not_active IP Right Cessation
- 1994-02-17 PL PL94302266A patent/PL177177B1/pl unknown
- 1994-02-17 AU AU55235/94A patent/AU671881C/en not_active Expired
- 1994-02-17 NZ NZ250906A patent/NZ250906A/en not_active IP Right Cessation
- 1994-02-17 JP JP02053294A patent/JP4033919B2/ja not_active Expired - Lifetime
- 1994-02-17 KR KR1019940002771A patent/KR100355686B1/ko not_active Expired - Lifetime
- 1994-02-17 NZ NZ314707A patent/NZ314707A/xx not_active IP Right Cessation
- 1994-02-18 HU HU9400481A patent/HU218281B/hu unknown
- 1994-02-18 SK SK195-94A patent/SK283021B6/sk not_active IP Right Cessation
- 1994-02-18 SK SK810-2001A patent/SK283022B6/sk not_active IP Right Cessation
- 1994-02-18 SI SI9400087A patent/SI9400087B/sl unknown
- 1994-02-18 ZA ZA941136A patent/ZA941136B/xx unknown
- 1994-02-18 UA UA94005526A patent/UA43829C2/uk unknown
- 1994-02-18 NO NO940564A patent/NO316601B1/no not_active IP Right Cessation
- 1994-02-18 FI FI940779A patent/FI110059B/fi not_active IP Right Cessation
- 1994-02-18 CN CN94101378A patent/CN1109557C/zh not_active Expired - Lifetime
- 1994-02-18 RU RU94005001A patent/RU2145234C1/ru active
- 1994-02-18 IL IL10870494A patent/IL108704A/xx not_active IP Right Cessation
- 1994-02-18 BR BR9400617A patent/BR9400617A/pt not_active Application Discontinuation
- 1994-02-18 HR HRP4305225.8 patent/HRP940117B1/xx not_active IP Right Cessation
- 1994-02-18 CA CA002115943A patent/CA2115943C/en not_active Expired - Lifetime
- 1994-02-21 MX MX9401312A patent/MX9401312A/es unknown
2000
- 2000-08-23 GR GR20000401924T patent/GR3034237T3/el unknown
2001
- 2001-02-27 KR KR1020010009932A patent/KR100372187B1/ko not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NZ314707A (en)	1999-02-25
SG46632A1 (en)	1998-02-20
RU2145234C1 (ru)	2000-02-10
HUT67117A (en)	1995-02-28
CA2115943C (en)	2003-08-05
ATE193653T1 (de)	2000-06-15
IL108704A (en)	2005-05-17
CN1109557C (zh)	2003-05-28
DE4305225A1 (de)	1994-08-25
HU218281B (en)	2000-07-28
IL108704A0 (en)	1994-05-30
AU671881C (en)	2004-01-15
HRP940117B1 (en)	2001-02-28
SK283022B6 (sk)	2003-02-04
TW387812B (en)	2000-04-21
CN1112019A (zh)	1995-11-22
NZ250906A (en)	1997-07-27
MX9401312A (es)	1994-08-31
AU5523594A (en)	1994-08-25
CA2115943A1 (en)	1994-08-20
SK19594A3 (en)	1994-09-07
CZ31294A3 (en)	1994-09-14
DK0611572T3 (da)	2000-09-25
PT611572E (pt)	2000-11-30
UA43829C2 (uk)	2002-01-15
BR9400617A (pt)	1994-09-27
FI940779A0 (fi)	1994-02-18
KR100355686B1 (ko)	2002-12-11
SI9400087A (en)	1994-12-31
CZ285768B6 (cs)	1999-11-17
ES2148247T3 (es)	2000-10-16
JP4033919B2 (ja)	2008-01-16
EP0611572B1 (de)	2000-06-07
CZ284314B6 (cs)	1998-10-14
AU671881B2 (en)	1996-09-12
EP0611572A2 (de)	1994-08-24
JPH06271476A (ja)	1994-09-27
DE59409389D1 (de)	2000-07-13
FI110059B (fi)	2002-11-29
SK283021B6 (sk)	2003-02-04
EP0947200A2 (de)	1999-10-06
HRP940117A2 (en)	1996-08-31
NO316601B1 (no)	2004-03-08
EP0611572A3 (de)	1995-01-11
FI940779L (fi)	1994-08-20
HU9400481D0 (en)	1994-12-28
SI9400087B (sl)	2002-02-28
GR3034237T3 (en)	2000-12-29
NO940564D0 (no)	1994-02-18
KR100372187B1 (ko)	2003-02-14
EP0947200B1 (de)	2015-03-11
EP0947200A3 (de)	2004-03-24
PL177177B1 (pl)	1999-10-29
ZA941136B (en)	1994-08-29

Publication	Publication Date	Title
NO940564L (zh)	1994-08-22
EP2016950A8 (en)	2009-07-01	Pharmaceutical composition comprising an exendin-4 peptide
GR3029791T3 (en)	1999-06-30	Improved immunogenic compositions against human gastrin 17
TW370532B (en)	1999-09-21	The use of cetrorelix and other nona and decapeptides in the preparation of a medicament for combating AIDS and for growth stimulation
CA2028140A1 (en)	1990-09-02	Novel bacteriocin compositions for use as enhanced broad range
HUT64567A (en)	1994-01-28	Method for producing new cyclosporines and preparations containing said compounds as active agent
EP0663835A1 (en)	1995-07-26	USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
NZ506631A (en)	2003-03-28	Formulations for the stabilisation of PEG-interferon alpha conjugates during and after lyophilization
ZA947894B (en)	1996-04-09	Compounds for medicinal use
AU1290288A (en)	1988-08-24	A process for treating infertility and an agent for use in the process
CA2144513A1 (en)	1994-03-31	Morphogen-induced periodontal tissue regeneration
CA2042934A1 (en)	1991-11-23	Treatment of ocular hypertension with an ocular synergistic combination
MY110998A (en)	1999-07-31	Antibiotic combination
BG101325A (en)	1998-01-30	Use of muramyl peptide compounds
NZ331674A (en)	2000-10-27	Use of antigenic preparations comprising Helicobacter catalase for treating or preventing Helicobacter infection
IT1255649B (it)	1995-11-09	Peptidi dotati di attivita' antibatterica
IT1264428B1 (it)	1996-09-23	Composizioni farmaceutiche per il trattamento della psoriasi

Legal Events

Date	Code	Title	Description
2014-03-03	MK1K	Patent expired